Abstract
Purpose :
Trabeculectomy is the primary surgical approach used to treat glaucoma. However, scarring of the filtering passage after surgery often leads to treatment failure. Our previous studies have demonstrated the anti-fibrotic effect of rosiglitazone (RSG). This study aimed to develop a drug release system called RSG/Pd@ZIF-8 PHBV film enabling the sustained release of RSG to prevent scarring.
Methods :
Palladium nanosheets (Pd) were first prepared under the protection of carbon monoxide. RSG/Pd@ZIF-8 NPs were synthesized using a one-pot method, where Pd and RSG were added during the ZIF-8 self-assembly process. The surface morphology of PHBV films doped with various concentrations of RSG/Pd@ZIF-8 NPs was observed using SEM. CCK8 assays, cell adhesion, hemolysis test, Photothermal effect and drug release test were conducted to evaluate the cytotoxicity, antibacterial action and anti-scarring effects of this system. Moreover, we confirmed its efficacy and biosafety in a rabbit eye model undergoing trabeculectomy.
Results :
In vitro, the film has the function of continuous Rosiglitazone (RSG) release, with accelerated release after laser irradiation. The film can inhibit 87.0% of E. coli and 97.1% of S. aureus. After implantation of the film, we observed a prolonged postoperative period for reducing intraocular pressure (IOP), increased survival rate of filtering blebs, and improved long-term surgical outcomes in vivo. Additionally, the film exhibited excellent biosafety.
Conclusions :
In summary, the designed sustained-release film in this study possesses the aforementioned functionalities, allowing for the regulation of anti-scarring drug release without causing harm post-surgery. This personalized and precise anti-scarring strategy represents a significant advancement.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.